Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 40.05 Billion KRW | -11.29% |
| 2022 | 45.15 Billion KRW | 16.24% |
| 2021 | 38.84 Billion KRW | 2.7% |
| 2020 | 37.81 Billion KRW | -6.87% |
| 2019 | 40.6 Billion KRW | 9.75% |
| 2018 | 37 Billion KRW | 5.27% |
| 2017 | 35.14 Billion KRW | -10.76% |
| 2016 | 39.38 Billion KRW | 11.63% |
| 2015 | 35.28 Billion KRW | -4.89% |
| 2014 | 37.09 Billion KRW | -9.37% |
| 2013 | 40.93 Billion KRW | 4.23% |
| 2012 | 39.27 Billion KRW | -7.19% |
| 2011 | 42.31 Billion KRW | -1.94% |
| 2010 | 43.15 Billion KRW | 7.94% |
| 2009 | 39.97 Billion KRW | 13.09% |
| 2008 | 35.35 Billion KRW | 1.21% |
| 2007 | 34.92 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.1 Billion KRW | 2.44% |
| 2024 Q2 | 11.11 Billion KRW | 11.86% |
| 2023 Q2 | 10.52 Billion KRW | 14.24% |
| 2023 Q1 | 9.21 Billion KRW | -10.21% |
| 2023 Q4 | 9.86 Billion KRW | 190.15% |
| 2023 FY | 40.05 Billion KRW | -11.29% |
| 2023 Q3 | -10.94 Billion KRW | -203.93% |
| 2022 Q3 | 10.66 Billion KRW | -15.61% |
| 2022 Q4 | 10.26 Billion KRW | -3.81% |
| 2022 FY | 45.15 Billion KRW | 16.24% |
| 2022 Q1 | 11.57 Billion KRW | 16.88% |
| 2022 Q2 | 12.64 Billion KRW | 9.23% |
| 2021 Q3 | 9.39 Billion KRW | -3.78% |
| 2021 Q4 | 9.9 Billion KRW | 5.42% |
| 2021 Q1 | 9.77 Billion KRW | 8.01% |
| 2021 Q2 | 9.76 Billion KRW | -0.16% |
| 2021 FY | 38.84 Billion KRW | 2.7% |
| 2020 Q1 | 10.21 Billion KRW | 3.71% |
| 2020 FY | 37.81 Billion KRW | -6.87% |
| 2020 Q2 | 8.63 Billion KRW | -15.4% |
| 2020 Q3 | 9.91 Billion KRW | 14.76% |
| 2020 Q4 | 9.05 Billion KRW | -8.68% |
| 2019 Q3 | 10.3 Billion KRW | -1.37% |
| 2019 Q2 | 10.44 Billion KRW | 4.33% |
| 2019 Q1 | 10.01 Billion KRW | 3.7% |
| 2019 FY | 40.6 Billion KRW | 9.75% |
| 2019 Q4 | 9.84 Billion KRW | -4.42% |
| 2018 FY | 37 Billion KRW | 5.27% |
| 2018 Q2 | 9.63 Billion KRW | 8.49% |
| 2018 Q4 | 9.65 Billion KRW | 9.38% |
| 2018 Q1 | 8.88 Billion KRW | -3.84% |
| 2018 Q3 | 8.82 Billion KRW | -8.4% |
| 2017 FY | 35.14 Billion KRW | -10.76% |
| 2017 Q2 | 8.67 Billion KRW | 6.71% |
| 2017 Q1 | 8.13 Billion KRW | -24.58% |
| 2017 Q4 | 9.23 Billion KRW | 1.53% |
| 2017 Q3 | 9.09 Billion KRW | 4.83% |
| 2016 Q3 | 9.63 Billion KRW | 0.01% |
| 2016 FY | 39.38 Billion KRW | 11.63% |
| 2016 Q4 | 10.78 Billion KRW | 11.96% |
| 2016 Q1 | 9.34 Billion KRW | 8.24% |
| 2016 Q2 | 9.63 Billion KRW | 3.1% |
| 2015 FY | 35.28 Billion KRW | -4.89% |
| 2015 Q4 | 8.62 Billion KRW | -15.55% |
| 2015 Q3 | 10.21 Billion KRW | 14.87% |
| 2015 Q2 | 8.89 Billion KRW | 6.15% |
| 2015 Q1 | 8.38 Billion KRW | -18.11% |
| 2014 FY | 37.09 Billion KRW | -9.37% |
| 2014 Q2 | 8.88 Billion KRW | 0.57% |
| 2014 Q4 | 10.23 Billion KRW | 11.86% |
| 2014 Q3 | 9.14 Billion KRW | 3.01% |
| 2014 Q1 | 8.83 Billion KRW | -24.64% |
| 2013 Q1 | 10.57 Billion KRW | -6.22% |
| 2013 Q2 | 9.49 Billion KRW | -10.17% |
| 2013 Q3 | 9.24 Billion KRW | -2.7% |
| 2013 FY | 40.93 Billion KRW | 4.23% |
| 2013 Q4 | 11.71 Billion KRW | 26.81% |
| 2012 Q4 | 11.27 Billion KRW | 12.79% |
| 2012 Q3 | 9.99 Billion KRW | 10.8% |
| 2012 Q2 | 9.02 Billion KRW | -1.87% |
| 2012 Q1 | 9.19 Billion KRW | 0.0% |
| 2012 FY | 39.27 Billion KRW | -7.19% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 42.31 Billion KRW | -1.94% |
| 2011 Q3 | 10.35 Billion KRW | -4.23% |
| 2011 Q2 | 10.81 Billion KRW | 0.62% |
| 2011 Q1 | 10.74 Billion KRW | -17.64% |
| 2010 Q3 | 10.44 Billion KRW | 1.52% |
| 2010 FY | 43.15 Billion KRW | 7.94% |
| 2010 Q4 | 13.05 Billion KRW | 24.94% |
| 2010 Q1 | 9.4 Billion KRW | -4.79% |
| 2010 Q2 | 10.28 Billion KRW | 9.37% |
| 2009 Q3 | 9.71 Billion KRW | -6.79% |
| 2009 Q1 | 9.98 Billion KRW | 23.56% |
| 2009 FY | 39.97 Billion KRW | 13.09% |
| 2009 Q2 | 10.42 Billion KRW | 4.43% |
| 2009 Q4 | 9.88 Billion KRW | 1.72% |
| 2008 Q2 | 10.07 Billion KRW | 11.43% |
| 2008 Q1 | 9.04 Billion KRW | -2.29% |
| 2008 FY | 35.35 Billion KRW | 1.21% |
| 2008 Q4 | 8.07 Billion KRW | -0.94% |
| 2008 Q3 | 8.15 Billion KRW | -19.09% |
| 2007 Q1 | 8.2 Billion KRW | 0.0% |
| 2007 Q4 | 9.25 Billion KRW | 5.41% |
| 2007 FY | 34.92 Billion KRW | 0.0% |
| 2007 Q2 | 8.74 Billion KRW | 6.66% |
| 2007 Q3 | 8.78 Billion KRW | 0.38% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 15.238% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 86.559% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 85.615% |
| HANDOK Inc. | 153.76 Billion KRW | 73.952% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | 42.131% |
| Yuhan Corporation | 489.94 Billion KRW | 91.825% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 86.952% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | 4.155% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 93.444% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | 44.358% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 77.001% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | 57.186% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | 65.088% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 15.238% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | 5.695% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | 46.631% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | 31.702% |
| JW Holdings Corporation | 301.25 Billion KRW | 86.705% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 84.651% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 90.199% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 83.235% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 68.627% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | 41.366% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | 39.084% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 77.103% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | 15.238% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 83.922% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 92.853% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 83.235% |
| Yuhan Corporation | 489.94 Billion KRW | 91.825% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 79.318% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | 42.344% |
| Suheung Co., Ltd. | 56.03 Billion KRW | 28.517% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 83.235% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 68.311% |
| Korea United Pharm Inc. | 118.21 Billion KRW | 66.118% |
| CKD Bio Corp. | 25.19 Billion KRW | -58.968% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 81.958% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 75.742% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | 39.695% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 68.627% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 88.58% |
| Boryung Corporation | 285.16 Billion KRW | 85.954% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | 54.247% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 77.001% |
| JW Lifescience Corporation | 20.26 Billion KRW | -97.68% |